Sir Thomas Fulton Wilson "Tom" McKillop, FRS, FRSE (born 19 March 1943) is a Scottish chemist, who was CEO of AstraZeneca PLC from 1999 until 2006 and chairman of the RBS Group from 2006 until 2008.
McKillop was born in Dreghorn, a small village in North Ayrshire. He was educated at Irvine Royal Academy and then Glasgow University, where he took a BSc (Hons) and PhD in Chemistry. He joined the ICI Petrochemical & Polymer Laboratory (later renamed the ICI Corporate Laboratory) at Runcorn in 1969 after post-doctoral research work in Paris. He moved to ICI Pharmaceuticals Division in 1975 and, having held a number of positions in Research, in 1989 he was appointed Technical Director of ICI with international responsibilities for research, development and production.
In 1993, ICI Pharmaceuticals demerged to become Zeneca, and in 1994 he was appointed chief executive officer of the new company. In April 1999, Zeneca merged with Astra to form AstraZeneca PLC. McKillop became chief executive officer (CEO) of the merged company. He retired from AstraZeneca on 1 January 2006, when David Brennan took over as AstraZeneca's CEO. McKillop became the chairman of the Royal Bank of Scotland (RBS). His brother, Alexander McKillop, was Professor of Organic Chemistry at the University of East Anglia from 1970–96.
McKillop then changed from chemistry to banking in 2006. He was chairman RBS from when it accrued a debt of £45 billion, working with CEO Fred Goodwin, who promoted aggressive expansion of the bank by acquiring other banks.
On 13 October 2008, British Prime Minister Gordon Brown announced a UK government bailout of £45 billion of new capital into Royal Bank of Scotland. RBS has accrued a further debt of £58 billion since 2008.